FDA: Discontinue Use of New England Compounding Center Products to Avoid Meningitis Contamination

The FDA is recommending healthcare professionals not use any products by the New England Compounding Center in Framingham, Mass., due to potentially contaminated medication causing a fungal meningitis outbreak, according to the American Society of Anesthesiologists.

The FDA has linked a fungal meningitis outbreak to potentially contaminated methylprednisolone acetate from NECC, though the exact source of the outbreak is still ongoing.

However, the FDA has observed fungal contamination from a sealed vial of the injectable steroid produced and distributed by NECC and is conducting additional testing to confirm the exact species of fungus.

As a precaution, governmental officials recommend discontinuing use of all NECC products while retaining and securing all remaining products purchased from NECC until the FDA provides instructions on disposal.

More Articles on Anesthesia:
Study: Lighter Anesthesia Does Not Improve Mortality Rates for Certain Patients
CBIZ Acquires ProMedical Anesthesia Billing Company
Lawmakers Concerned by Policy to Allow Patients to Report Medical Mistakes




Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast